Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of PE0116 combined with PE0105 in advanced solid tumors
CTR20232109Phase 2Active
- Sponsor
- Shanghai HyaMab Biotechnology
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PE0116, PE0105 in Nonhematologic neoplasms, ovarian cancer, Cervical Cancer (CC), renal cell carcinoma (RCC), head and neck cancer (HNC), sponsored by Shanghai HyaMab Biotechnology. Started Sep 2023; status: active.
02
Drugs
PE0116PE0105
03
Conditions
Nonhematologic neoplasmsovarian cancerCervical Cancer (CC)renal cell carcinoma (RCC)head and neck cancer (HNC)
Beyond the preview
Go deeper on CTR20232109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232109.